“For the full year 2026, we anticipate core revenue growth in the 3% to 6% range.”

In context

“for future menu additions and anticipated continued expansion of our leading global installed base. Now let's briefly look ahead at the expectations for the first quarter and the full year 2026. Looking across the portfolio, we are assuming bioprocessing growth will be similar to 2025, including continued strength in consumables, driven by healthy growth in monoclonal antibody demand and our strong positioning across the biologics workflow. In life sciences, we are assuming a modest improvement in end markets, but assume growth will remain below historical levels given the current macro environment. In diagnostics, we are assuming higher growth in 2026 due to moving past the peak of headwinds from policy changes in China and our expectation that we will continue to execute well globally. For the full year 2026, we anticipate core revenue growth in the 3% to 6% range. Additionally, we are initiating full-year adjusted diluted EPS guidance in the range of $8.35 to $8.50. In the first quarter, we expect core revenue to be up low single digits. Additionally, we expect the first-quarter adjusted operating profit margin of approximately 28.5%. So to wrap up, we are pleased with our solid finish to the year and proud of the work our teams did in 2025 to reliably support our customers through a dynamic macro environment. They did a tremendous job staying focused on what we can control, running the Danaher business system playbook to offset cost pressures and deliver productivity gains while continuing to invest in innovation for the long term. So looking ahead, we are encouraged by the momentum building across our portfolio and expect growth to accelerate as”